In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 11, 2013, Pages 5707-5709

  Walkty, A ^a,b   Karlowsky, J A ^a,b   Adam, H ^a,b   Baxter, M ^b   Lagace Wiens P ^a,b   Hoban, D J ^a,b   Zhanel, G G ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM; BETA LACTAMASE AMPC; CEFTAZIDIME; CEFTOLOZANE; CIPROFLOXACIN; COLISTIN; EXTENDED SPECTRUM BETA LACTAMASE; MEROPENEM; METALLO BETA LACTAMASE; PENICILLIN BINDING PROTEIN; PIPERACILLIN PLUS TAZOBACTAM; TAZOBACTAM; TOBRAMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BLOOD; BROTH DILUTION; CANADA; CELL MEMBRANE PERMEABILITY; EFFUSION; EMERGENCY WARD; HOSPITAL; HUMAN; IN VITRO STUDY; INTENSIVE CARE UNIT; MILK; MINIMUM INHIBITORY CONCENTRATION; MORPHOLOGICAL TRAIT; MORTALITY; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SURGICAL WARD; TRANSPORT MEDIUM; UPREGULATION; URINE; WARD; WOUND;

ANTI-BACTERIAL AGENTS; CANADA; CEFTAZIDIME; CEPHALOSPORINS; CROSS INFECTION; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HOSPITALS; HUMANS; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES;

EID: 84885898863     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01404-13     Document Type: Article

References (20)

1. Zhanel GG, DeCorby M, Adam H, Mulvey MR, McCracken M, Lagace-Wiens P, Nichol KA, Wierzbowski A, Baudry PJ, Tailor F, Karlowsky JA, Walkty A, Schweizer F, Johnson J, Canadian Antimicrobial Resistance Alliance, Hoban DJ. 2010. Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: Results of the Canadian Ward Surveillance Study (CANWARD 2008). Antimicrob. Agents Chemother. 54: 4684-4693.
2. Gaynes R, Edwards JR, National Nosocomial Infections Surveillance System. 2005. Overview of nosocomial infections caused by gramnegative bacilli. Clin. Infect. Dis. 41:848-854.
3. Biedenbach DJ, Moet GJ, Jones RN. 2004. Occurrence and antimicrobial resistance pattern comparisons among bloodstream isolates from the SENTRY antimicrobial surveillance program (1997-2002). Diagn. Microbiol. Infect. Dis. 50:59-69.
4. Mathai D, Jones RN, Pfaller MA, Participant Group North America SENTRY. 2001. Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: A report from the SENTRY antimicrobial surveillance program (North America). Diagn. Microbiol. Infect. Dis. 40:129-136.
5. Walkty A, Baxter M, Adam H, Karlowsky JA, Lagace-Wiens P, Hoban DJ, Zhanel GG. 2012. Antimicrobial susceptibility of Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals: CANWARD 2008-2011. Diagn. Microbiol. Infect. Dis. 73:361-364.
6. Lodise TP, Jr, Patel N, Kwa A, Graves J, Furuno JP, Graffunder E, Lomaestro B, McGregor JC. 2007. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: Impact of delayed appropriate antibiotic selection. Antimicrob. Agents Chemother. 51:3510-3515.
7. Tumbarello M, Repetto E, Trecarichi EM, Bernardini C, De Pascale G, Parisini A, Rossi M, Molinari MP, Spanu T, Viscoli C, Cauda R, Bassetti M. 2011. Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: Risk factors and mortality. Epidemiol. Infect. 139:1740-1749.
8. Tam VH, Rogers CA, Chang KT, Weston JS, Caeiro JP, Garey KW. 2010. Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob. Agents Chemother. 54:3717-3722.
9. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. 2006. Multidrug-resistant Pseudomonas aeruginosa: Risk factors and clinical impact. Antimicrob. Agents Chemother. 50:43-48.
10. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Jr, Gilbert D, Rice LB, Scheld M, Spelberg B, Bartlett J. 2009. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48:1-12.
11. Bulik CC, Christensen H, Nicolau DP. 2010. In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance. Antimicrob. Agents Chemother. 54:557-559.
12. Juan C, Zamorano L, Perez JL, Ge Y, Oliver A, Spanish Group for the Study of Pseudomonas, Spanish Network for Research in Infectious Diseases. 2010. Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205) against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. Antimicrob. Agents Chemother. 54: 846-851.
13. Moya B, Zamorano L, Juan C, Perez JL, Ge Y, Oliver A. 2010. Activity of a new cephalosporin, CXA-101 (FR264205), against -lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. Antimicrob. Agents Chemother. 54:1213-1217.
14. Livermore DM. 2002. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: Our worst nightmare? Clin. Infect. Dis. 34:634-640.
15. Takeda S, Ishii Y, Hatano K, Tateda K, Yamaguchi K. 2007. Stability of FR264205 against AmpC -lactamase of Pseudomonas aeruginosa. Int. J. Antimicrob. Agents 30:443-445.
16. Moya B, Zamorano L, Juan C, Ge Y, Oliver A. 2010. Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 54:3933-3937.
17. Takeda S, Nakai T, Wakai Y, Ikeda F, Hatano K. 2007. In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 51:826-830.
18. Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing: 22nd informational supplement M100-S22. CLSI, Wayne, PA.
19. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 7th ed. Approved standard M7-A7. CLSI, Wayne, PA.
20. Sader HS, Rhomberg PR, Farrell DJ, Jones RN. 2011. Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Antimicrob. Agents Chemother. 55:2390-2394.